Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 16/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24791076 | 0.82 | FFAR4 (0.51) | FFAR4FFAR1 | |
| SCHEMBL6621385 | 0.81 | ITGB3 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL16969163 | 0.80 | FFAR4 (0.50) | FFAR4FFAR1 | |
| SCHEMBL44579 | 0.79 | GABRA5 (0.75) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL6620395 | 0.79 | SLC6A1 (0.44) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL1222257 | 0.79 | BRD4 (0.37) | FFAR4FFAR1 | |
| SCHEMBL23603990 | 0.78 | FFAR4 (0.51) | FFAR4FFAR1 | |
| Hydrochloric Acid SCHEMBL1223805 | 0.78 | BRD4 (0.36) | FFAR4FFAR1 | |
| SCHEMBL6620403 | 0.77 | FFAR4 (0.46) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL1967312 | 0.77 | GABRA5 (0.72) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024001839-A1 | HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2012009217-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-2064187-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1224186-B1 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | MILLENNIUM PHARM INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2003-09-11 | — | — | US | disclosed |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
| US-6528534-B2 | Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1224186-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2002-01-31 | — | — | US | disclosed |
| US-6291469-B1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| WO-2001030780-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| EP-0854869-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011940-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | SLC6A1 584/4885GABRA5 1731/4885GABRB2 1115/4885 |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, FGB | SLC6A1 3924/4885GABRA5 2065/4885GABRB2 2274/4885 |
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | SLC6A1 3021/4885GABRA5 1116/4885GABRB2 1160/4885 |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | SLC6A1 3021/4885GABRA5 1116/4885GABRB2 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.